Although the role of CASP2 in regulating p53 stability during the cell cycle and DDR is still debated in different cancer contexts,[30] treatment of the resistant cells with a CASP2 inhibiting peptide (Ac‐VDVAD‐CHO) resulted in higher levels of MDM2 p90 and simultaneous downregulation of MDM2 p60 (Figure 6H). This evidence concerns the gene CASP2 and cancer.